GlassScriptPhysician profile
Brian Golden
NPI 1558334102
$18,952.06
in general payments reported to CMS, 2019-2025
54 companies · $3,302 in 2025
The $3,302 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,232 · 2020: $2,068 · 2021: $3,034 · 2022: $3,121 · 2023: $2,447 · 2024: $2,749 · 2025: $3,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,492 · Education: $5.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,491.68 |
| Education | $5.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,435.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $2,027.04 | 2019-2025 | Korlym |
| Amgen INC. | $1,944.15 | 2019-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,358.15 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,326.44 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $1,258.12 | 2019-2025 | |
| Lilly USA, LLC | $1,189.30 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $817.44 | 2019-2025 | Freestyle Libre |
| Abbvie INC. | $684.59 | 2019-2025 | |
| Radius Health, INC. | $656.88 | 2019-2025 | Tymlos |
| Mannkind Corporation | $587.71 | 2020-2025 | |
| Xeris Pharmaceuticals, INC. | $512.77 | 2022-2025 | Recorlev |
| Medtronic, INC. | $430.53 | 2021-2025 | Minimed 780g |
| Amarin Pharma, INC. | $399.80 | 2019-2022 | |
| Insulet Corporation | $366.87 | 2019-2025 | Omnipod |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Golden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.